Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 02/11/2026 | Q4 | $288.9M | -- | -- | -$0.17 | -- |
| 11/12/2025 | Q3 | $245M | $249.6M | -$1.17 | -$0.18 | -$0.99 |
| 08/07/2025 | Q2 | $166.8M | $179.3M | -$0.73 | -$1.52 | $0.79 |
| 05/01/2025 | Q1 | $107.9M | $106.3M | -$1.66 | -$1.71 | $0.06 |
| 02/12/2025 | Q4 | $123.2M | $185.5M | -$0.69 | -$0.96 | $0.28 |
| 11/14/2024 | Q3 | $76.5M | $63.5M | -$1.89 | -$1.57 | -$0.32 |
| 09/03/2024 | Q2 | $94.2M | $38.8M | -$2.06 | -$1.40 | -$0.65 |
| 05/02/2024 | Q1 | $85.6M | $104.2M | -$2.50 | -$1.52 | -$0.98 |
| 02/07/2024 | Q4 | $92.1M | $148.3M | -$1.66 | -$1.90 | $0.24 |
| 11/07/2023 | Q3 | -- | -- | -$3.14 | -$2.37 | -$0.76 |
| 09/05/2023 | Q2 | -- | -- | -$2.36 | -$2.80 | $0.45 |
| 04/27/2023 | Q1 | -- | -- | -$2.13 | -$2.89 | $0.77 |
| 02/16/2023 | Q4 | -- | -- | -$3.78 | -$2.77 | -$1.02 |
| 11/02/2022 | Q3 | -- | -- | -$3.05 | -$2.52 | -$0.53 |
| 08/10/2022 | Q2 | -- | -- | -$1.56 | -$2.28 | $0.73 |
| 05/11/2022 | Q1 | -- | -- | -$2.48 | -$2.15 | -$0.33 |
| 03/02/2022 | Q4 | -- | -- | -$2.14 | -$2.59 | $0.46 |
| 11/10/2021 | Q3 | -- | -- | -- | -$2.66 | -- |
| 08/25/2021 | Q2 | -- | -- | -$3.01 | -$2.64 | -$0.37 |
| 05/27/2021 | Q1 | -- | -- | -$1.41 | -$2.27 | $0.86 |
| 03/10/2021 | Q4 | -- | -- | -$3.15 | -$1.88 | -$1.27 |
| 11/11/2020 | Q3 | -- | -- | -$2.70 | -$1.87 | -$0.83 |
| 08/27/2020 | Q2 | -- | -- | -$2.17 | -$1.60 | -$0.57 |
| 05/19/2020 | Q1 | -- | -- | -$1.46 | -$1.40 | -$0.05 |
| 12/31/2019 | Q4 | -- | -- | -$1.88 | -$1.32 | -$0.56 |
| 11/18/2019 | Q3 | -- | -- | -$0.59 | -$1.28 | $0.69 |
| 08/28/2019 | Q2 | -- | -- | -- | -$1.33 | -- |
| 04/03/2019 | Q1 | -- | -- | -- | -$1.14 | -- |
| 12/31/2018 | Q4 | -- | -- | -- | -$1.13 | -- |
| 11/28/2018 | Q3 | -- | -- | -- | -$1.20 | -- |
| 08/29/2018 | Q2 | -- | -- | -- | -$0.99 | -- |
| 05/30/2018 | Q1 | -- | -- | -- | -- | -- |
| 03/28/2018 | Q4 | -- | -- | -- | -- | -- |
| 11/16/2017 | Q3 | -- | -- | -- | -- | -- |
| 08/18/2017 | Q2 | -- | -- | -- | -- | -- |
| 03/31/2017 | Q1 | -- | -- | -- | -- | -- |
| 12/31/2016 | Q4 | -- | -- | -- | -- | -- |
| 11/30/2016 | Q3 | -- | -- | -- | -- | -- |
| 08/31/2016 | Q2 | -- | -- | -- | -- | -- |
| 03/31/2016 | Q1 | -- | -- | -- | -- | -- |
| 12/31/2015 | Q4 | -- | -- | -- | -- | -- |
Ascendis Pharma A/S reported $249.6M worth of top line sales in its most recent quarter.
Ascendis Pharma A/S announced earnings per share of -$1.17 which represents a miss of analyst forecast a -$0.18 per share.
Ascendis Pharma A/S reported $219.4M that represents $3.61 per share over the last quarter.
Ascendis Pharma A/S's earnings are forecast to decrease from -$7.06 per share to -$6.78 per share next year representing a decrease of -46.48%.
Ascendis Pharma A/S's next earnings date is February 11, 2026.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.